Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy
with Alendronate or Risedronate</title><author><name sortKey="Miller, Paul D" sort="Miller, Paul D" uniqKey="Miller P" first="Paul D." last="Miller">Paul D. Miller</name></author><author><name sortKey="Delmas, Pierre D" sort="Delmas, Pierre D" uniqKey="Delmas P" first="Pierre D." last="Delmas">Pierre D. Delmas</name></author><author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name></author><author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name></author><author><name sortKey="Luckey, Marjorie" sort="Luckey, Marjorie" uniqKey="Luckey M" first="Marjorie" last="Luckey">Marjorie Luckey</name></author><author><name sortKey="Adachi, Jonathan" sort="Adachi, Jonathan" uniqKey="Adachi J" first="Jonathan" last="Adachi">Jonathan Adachi</name></author><author><name sortKey="Saag, Kenneth" sort="Saag, Kenneth" uniqKey="Saag K" first="Kenneth" last="Saag">Kenneth Saag</name></author><author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name></author><author><name sortKey="Seeman, Ego" sort="Seeman, Ego" uniqKey="Seeman E" first="Ego" last="Seeman">Ego Seeman</name></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name></author><author><name sortKey="Meeves, Suzanne" sort="Meeves, Suzanne" uniqKey="Meeves S" first="Suzanne" last="Meeves">Suzanne Meeves</name></author><author><name sortKey="Lang, Thomas F" sort="Lang, Thomas F" uniqKey="Lang T" first="Thomas F." last="Lang">Thomas F. Lang</name></author><author><name sortKey="Bilezikian, John P" sort="Bilezikian, John P" uniqKey="Bilezikian J" first="John P." last="Bilezikian">John P. Bilezikian</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18682511</idno><idno type="pmc">5399468</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399468</idno><idno type="RBID">PMC:5399468</idno><idno type="doi">10.1210/jc.2008-0353</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">001920</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001920</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy
with Alendronate or Risedronate</title><author><name sortKey="Miller, Paul D" sort="Miller, Paul D" uniqKey="Miller P" first="Paul D." last="Miller">Paul D. Miller</name></author><author><name sortKey="Delmas, Pierre D" sort="Delmas, Pierre D" uniqKey="Delmas P" first="Pierre D." last="Delmas">Pierre D. Delmas</name></author><author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name></author><author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name></author><author><name sortKey="Luckey, Marjorie" sort="Luckey, Marjorie" uniqKey="Luckey M" first="Marjorie" last="Luckey">Marjorie Luckey</name></author><author><name sortKey="Adachi, Jonathan" sort="Adachi, Jonathan" uniqKey="Adachi J" first="Jonathan" last="Adachi">Jonathan Adachi</name></author><author><name sortKey="Saag, Kenneth" sort="Saag, Kenneth" uniqKey="Saag K" first="Kenneth" last="Saag">Kenneth Saag</name></author><author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name></author><author><name sortKey="Seeman, Ego" sort="Seeman, Ego" uniqKey="Seeman E" first="Ego" last="Seeman">Ego Seeman</name></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name></author><author><name sortKey="Meeves, Suzanne" sort="Meeves, Suzanne" uniqKey="Meeves S" first="Suzanne" last="Meeves">Suzanne Meeves</name></author><author><name sortKey="Lang, Thomas F" sort="Lang, Thomas F" uniqKey="Lang T" first="Thomas F." last="Lang">Thomas F. Lang</name></author><author><name sortKey="Bilezikian, John P" sort="Bilezikian, John P" uniqKey="Bilezikian J" first="John P." last="Bilezikian">John P. Bilezikian</name></author></analytic><series><title level="j">The Journal of Clinical Endocrinology and Metabolism</title><idno type="ISSN">0021-972X</idno><idno type="eISSN">1945-7197</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><bold>Background:</bold> Anabolic responsiveness to teriparatide can be blunted or
delayed in patients previously treated with alendronate. The extent of this effect is
different for other antiresorptives. This study evaluated the early anabolic effects of
teriparatide in postmenopausal women with osteoporosis previously treated with alendronate
or risedronate.</p><p><bold>Methods:</bold> Patients treated for at least 24 months with alendronate or
risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The
primary endpoint was a comparison of changes from baseline in N-terminal propeptide of
type 1 collagen after 3 months between prior bisphosphonate groups. We also examined
changes in other bone turnover markers, bone mineral density (BMD), and relationships
between early changes in bone turnover markers and 12-month areal and volumetric BMD.</p><p><bold>Results:</bold> In the prior risedronate group, the N-terminal propeptide of type 1
collagen increase was significantly greater after 3 months of teriparatide than in the
prior alendronate group (mean ± <sc>se</sc>, 86.0 ± 5.6 <italic>vs</italic>. 61.2 ± 5.3
ng/ml, respectively; <italic>P</italic> < 0.001). Findings were similar for the other
bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were
also greater in the prior risedronate group (<italic>P</italic> < 0.05). Early changes
in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12
months (Spearman r = 0.45). Teriparatide was well tolerated.</p><p><bold>Conclusion:</bold> This nonrandomized but prospective study suggests that there may
be differences in anabolic responsiveness to teriparatide as a function of the type of
prior bisphosphonate exposure.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Endocrinol. Metab</journal-id><journal-id journal-id-type="publisher-id">jcem</journal-id><journal-title-group><journal-title>The Journal of Clinical Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">0021-972X</issn><issn pub-type="epub">1945-7197</issn><publisher><publisher-name>Endocrine Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18682511</article-id><article-id pub-id-type="pmc">5399468</article-id><article-id pub-id-type="other">6096</article-id><article-id pub-id-type="doi">10.1210/jc.2008-0353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrine Care</subject></subj-group><subj-group subj-group-type="subject"><compound-subject><compound-subject-part content-type="code">CA</compound-subject-part><compound-subject-part content-type="text">Cardiac Radiology</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">GI</compound-subject-part><compound-subject-part content-type="text">Gastrointestinal
Radiology</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy
with Alendronate or Risedronate</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Paul D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Delmas</surname><given-names>Pierre D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lindsay</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="author"><name><surname>Watts</surname><given-names>Nelson B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Luckey</surname><given-names>Marjorie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Adachi</surname><given-names>Jonathan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saag</surname><given-names>Kenneth</given-names></name></contrib><contrib contrib-type="author"><name><surname>Greenspan</surname><given-names>Susan L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Seeman</surname><given-names>Ego</given-names></name></contrib><contrib contrib-type="author"><name><surname>Boonen</surname><given-names>Steven</given-names></name></contrib><contrib contrib-type="author"><name><surname>Meeves</surname><given-names>Suzanne</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Thomas F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bilezikian</surname><given-names>John P.</given-names></name><on-behalf-of>for the <italic>O</italic>pen-label Study to Determine How
<italic>P</italic>rior <italic>T</italic>herapy with <italic>A</italic>lendronate or
Risedronate in Post<italic>m</italic>enopausal Women with Osteoporosis
<italic>I</italic>nfluence<italic>s</italic> the Clinical
<italic>E</italic>ffectiveness of Teriparatide Investigators</on-behalf-of><xref rid="FN1"><sup>1</sup></xref></contrib><aff>Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado 80227; Institut National de la Santé et de la Recherche Médicale Research Unit 831 (P.D.D.) and Claude Bernard University Lyon 1, 69372 Lyon, France; Regional Bone Center (R.L.), Helen Hayes Hospital, West Haverstraw, New York 10993; University of Cincinnati Bone Health and Osteoporosis Center (N.B.W.), Cincinnati, Ohio 45219; St. Barnabas Osteoporosis Center (M.L.), Livingston, New Jersey 07039; St. Joseph’s Healthcare (J.A.), McMaster University, Hamilton, Ontario, Canada L8S4L8; Division of Clinical Immunology and Rheumatology (K.S.), University of Alabama at Birmingham, Birmingham, Alabama 35233; University of Pittsburgh Medical Center (S.L.G.), Pittsburgh, Pennsylvania 15213; Endocrinology Department (E.S.), Austin Health, University of Melbourne, Victoria 3010, Australia; Bone Research Unit (S.B.), Leuven University, Department of Experimental Medicine, B-3000 Leuven, Belgium; sanofi-aventis (S.M.), Bridgewater, New Jersey 08807; Department of Radiology (T.F.L.), Center for Molecular and Functional Imaging, University of California at San Francisco, San Francisco, California 94107; and Division of Endocrinology (J.P.B.), Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons, New York, New York 10021</aff></contrib-group><author-notes><corresp>Address all correspondence and requests for reprints to: Paul D. Miller, M.D.,
Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Suite 250, Lakewood,
Colorado 80227. E-mail: <email>MillerCCBR@aol.com</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2008</year><string-date>October 1, 2008</string-date></pub-date><volume>93</volume><issue>10</issue><fpage>3785</fpage><lpage>3793</lpage><history><date date-type="accepted"><day>24</day><month>7</month><year>2008</year></date><date date-type="received"><day>12</day><month>2</month><year>2008</year></date></history><permissions><copyright-statement>© 2008 by The Endocrine Society</copyright-statement><copyright-year>2008</copyright-year></permissions><self-uri content-type="pdf" xlink:href="jc.2008-0353.pdf"></self-uri><abstract><p><bold>Background:</bold> Anabolic responsiveness to teriparatide can be blunted or
delayed in patients previously treated with alendronate. The extent of this effect is
different for other antiresorptives. This study evaluated the early anabolic effects of
teriparatide in postmenopausal women with osteoporosis previously treated with alendronate
or risedronate.</p><p><bold>Methods:</bold> Patients treated for at least 24 months with alendronate or
risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The
primary endpoint was a comparison of changes from baseline in N-terminal propeptide of
type 1 collagen after 3 months between prior bisphosphonate groups. We also examined
changes in other bone turnover markers, bone mineral density (BMD), and relationships
between early changes in bone turnover markers and 12-month areal and volumetric BMD.</p><p><bold>Results:</bold> In the prior risedronate group, the N-terminal propeptide of type 1
collagen increase was significantly greater after 3 months of teriparatide than in the
prior alendronate group (mean ± <sc>se</sc>, 86.0 ± 5.6 <italic>vs</italic>. 61.2 ± 5.3
ng/ml, respectively; <italic>P</italic> < 0.001). Findings were similar for the other
bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were
also greater in the prior risedronate group (<italic>P</italic> < 0.05). Early changes
in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12
months (Spearman r = 0.45). Teriparatide was well tolerated.</p><p><bold>Conclusion:</bold> This nonrandomized but prospective study suggests that there may
be differences in anabolic responsiveness to teriparatide as a function of the type of
prior bisphosphonate exposure.</p></abstract><custom-meta-group><custom-meta><meta-name>hwp-legacy-fpage</meta-name><meta-value>3785</meta-value></custom-meta><custom-meta><meta-name>hwp-legacy-dochead</meta-name><meta-value>Original Article</meta-value></custom-meta></custom-meta-group></article-meta><notes><sec sec-type="arthw-remark"><title></title><p>Postmenopausal women with osteoporosis previously treated for at least 2 years with
risedronate have a greater response to 1 year of teriparatide than those previously
treated with alendronate.</p></sec></notes></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001920 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001920 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |